Acadia Pharmaceuticals Inc
trofinetide
Rett syndrome
Countdown
146days
Phase 2 readout · Nov 30, 2026
What's at stake
Phase 2 trial results for trofinetide in Rett syndrome are due Nov 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Accelerated enrollment in the trofinetide clinical trial in Japan, with topline results now anticipated in the September to November 2026 timeframe.”